Log in
Enquire now
‌

US Patent 11524949 Degraders and Degrons for targeted protein degradation

Patent 11524949 was granted and assigned to C4 Therapeutics on December, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
C4 Therapeutics
C4 Therapeutics
0
Date Filed
May 14, 2020
0
Date of Patent
December 13, 2022
0
Patent Applicant
C4 Therapeutics
C4 Therapeutics
0
Patent Application Number
16874475
0
Patent Citations
‌
US Patent 10646575 Heterocyclic degronimers for target protein degradation
‌
US Patent 10351568 Compositions and methods for enhancing proteasome activity
‌
US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation
‌
US Patent 10905768 Heterocyclic degronimers for target protein degradation
‌
US Patent 10660968 Spirocyclic degronimers for target protein degradation
0
Patent Citations Received
‌
US Patent 11802131 Glutarimides for medical treatment
Patent Inventor Names
Christopher G. Nasveschuk
0
Minsheng He
0
Kiel Lazarski
0
James A. Henderson
0
Andrew J. Phillips
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11524949
0
Patent Primary Examiner
‌
Noble E Jarrell
0
CPC Code
‌
C07D 221/22
0
‌
C07D 401/12
0
‌
C07D 413/04
0
‌
C07D 401/04
0

Find more entities like US Patent 11524949 Degraders and Degrons for targeted protein degradation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.